Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, EDWARDS LIFESCIENCES CORPORATION reported revenue of $6.07B, up 11.5% year over year. Operating margin was 20.8% and net margin 17.7%, on a free-cash-flow margin of 22.0% with capital expenditure at 4.3% of revenue. Every figure is computed directly from EW's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $6.07B | 20.8% | 17.7% |
| FY2024 | $5.44B | 25.3% | 76.7% |
| FY2023 | $5.01B | 26.1% | 28.0% |
| FY2022 | $4.46B | 33.6% | 34.1% |
| FY2021 | $5.23B | 32.3% | 28.7% |
How does EW compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.